Analytical Data
-
Gene name
ZG16B
- Application
-
Alternative Names
JCLN2; Jacalin-Like Lectin Domain Containing 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96DA0
-
Expression Region
Gly17~Arg172
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ZG16B, a member of the C-type lectin family, has garnered significant interest in biomedical research due to its potential roles in immune response and gut homeostasis. Expressed primarily in the intestine, ZG16B plays a crucial role in recognizing specific glycans on pathogens, thereby influencing the immune system's ability to detect and respond to microbial threats. Recent studies have highlighted its involvement in modulating inflammatory responses, suggesting that ZG16B may be a key player in maintaining gut health and preventing diseases such as inflammatory bowel disease (IBD). Additionally, its expression is linked to the regulation of microbial composition in the gut, indicating a dual function in both immunity and microbiota balance. Given the rising prevalence of gut-related disorders worldwide, understanding the mechanisms by which ZG16B operates could provide valuable insights for therapeutic interventions. Ongoing research aims to elucidate the structural characteristics of ZG16B, its ligand binding properties, and its signaling pathways, potentially paving the way for targeted treatments that leverage this protein's unique functions in health and disease.
